| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2023-023 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、会议召开情况 三诺生物传感股份有限公司（以下简称"公司"）第五届监事会第九次会议 于 2024 年 4 月 24 日（星期三）下午 14 时在公司会议室以现场方式召开。本次 会议的通知已于 2024 年 4 月 14 日通过书面或电子邮件方式送达全体监事。应出 席本次会议的监事 3 人，实际出席本次会议的监事 3 人，分别为欧阳柏伸先生、 陈春耕先生和黄绍波先生。会议由监事会主席欧阳柏伸先生召集并主持，公司董 事会秘书郑霁耘女士列席了会议。会议的召集、召开符合《公司法》及《公司章 程》、《公司监事会议事规则》的规定。 二、会议审议情况 经与会监事认真审议，本次会议以现场表决方式通过如下决议： （一）审议并通过《关于〈公司 2023 年监事会工作报告〉的议案》 2023 年，公司监事会严格按照《公司法》、《证券法》、《深圳证券 ...

三诺生物传感股份有限公司 三诺生物传感股份有限公司 2023 年度董事会工作报告 2023年度，三诺生物传感股份有限公司（以下简称"公司"）董事会严格按 照《公司法》、《证券法》等法律法规以及《公司章程》、《公司董事会议事规 则》等相关规定和要求，本着对公司及全体股东负责的原则，积极履行股东大会 赋予的董事会各项职权，勤勉尽责地开展董事会各项工作，贯彻落实股东大会的 各项决议，规范运作，科学决策，持续推动公司治理水平的提高和公司各项业务 发展，保障公司健康、可持续发展，切实维护公司广大中小投资者的合法权益。 现将公司董事会2023年度的主要工作情况报告如下： 一、2023 年度总体经营情况和财务状况 | | | | | （单位：万元） | | --- | --- | --- | --- | --- | | 项 | 目 | 2023 年 | 2022 年 | 较上年增减 | | 流动资产 | | 210,634.08 | 237,522.86 | -11.32% | | 非流动资产 | | 382,063.10 | 382,026.46 | 0.01% | | 资产合计 | | 592,697.18 | 619 ...

三诺生物第三期员工持股计划（草案修订稿） 三诺生物传感股份有限公司 第三期员工持股计划（草案修订稿） 证券简称：三诺生物 证券代码：300298 二〇二四年四月 三诺生物第三期员工持股计划（草案修订稿） 声明 本公司及全体董事、监事保证本员工持股计划及其摘要不存在虚假记载、误 导性陈述或重大遗漏，并对其真实性、准确性和完整性承担个别和连带法律责任。 三诺生物第三期员工持股计划（草案修订稿） 风险提示 （一）三诺生物传感股份有限公司（以下简称"三诺生物"或"公司"）第 三期员工持股计划需经公司股东大会审议通过后方可实施，第三期员工持股计划 能否获得公司股东大会批准、能否达到计划目标存在不确定性； （二）有关第三期员工持股计划的具体的资金来源、出资比例、实施方案等 属初步结果，能否完成实施，存在不确定性； （三）公司后续将根据相关规定披露相关进展情况，敬请广大投资者谨慎决 策，注意投资风险。 三诺生物第三期员工持股计划（草案修订稿） 特别提示 1．《三诺生物传感股份有限公司第三期员工持股计划》（以下简称"第三 期持股计划"或"本员工持股计划"）系公司依据《中华人民共和国公司法》（以 下简称"《公司法》"）、《中华 ...

经中国证券监督管理委员会核发的《关于同意三诺生物传感股份有限公司向不特 定对象发行可转换公司债券注册的批复》 【证监许可﹝2020﹞2951】号批准，公司 获准向不特定对象发行可转换公司债券 5,000,000 张，共计募集资金总额为人民币 500,000,000.00 元，本次募集资金扣除承销及保荐费用人民币 7,000,000.00 元（含税） 中信证券股份有限公司 关于三诺生物传感股份有限公司 2023年度募集资金存放与使用情况的专项核查意见 根据中国证券监督管理委员会《证券发行上市保荐业务管理办法（2023年修订）》 《深圳证券交易所创业板股票上市规则（2023年修订）》《深圳证券交易所上市公司 自律监管指引第2号——创业板上市公司规范运作》相关要求，中信证券股份有限公 司（以下简称"中信证券"、"保荐机构"）作为三诺生物传感股份有限公司（以下 简称"三诺生物"或"公司"）的保荐机构，对公司2023年度募集资金存放与使用情 况进行了核查。具体情况如下： 一、募集资金基本情况 （一）募集资金金额及到账时间 1、2018年重组配套募集资金基本情况 经中国证券监督管理委员会核发的《关于核准三诺生物传感股份有 ...

根据中国证券监督管理委员会《证券发行上市保荐业务管理办法（2023年修订）》 《深圳证券交易所创业板股票上市规则（2023年修订）》《深圳证券交易所上市公司 自律监管指引第2号——创业板上市公司规范运作》相关要求，中信证券股份有限公 司（以下简称"中信证券"、"保荐机构"）作为三诺生物传感股份有限公司（以下 简称"三诺生物"或"公司"）的保荐机构，对公司2023年度内部控制自我评价报告 进行了核查。根据《三诺生物传感股份有限公司2023年度内部控制自我评价报告》中 所述，具体情况如下： 一、公司内部控制评价结论 根据公司财务报告内部控制重大缺陷的认定情况，截至内部控制评价报告基准日， 公司不存在财务报告内部控制重大缺陷，董事会认为，公司已按照企业内部控制规范 体系和相关规定的要求在所有重大方面保持了有效的财务报告内部控制。 根据公司非财务报告内部控制重大缺陷认定情况，截至内部控制评价报告基准日， 公司未发现非财务报告内部控制重大缺陷。 自内部控制评价报告基准日至内部控制评价报告发出日之间未发生影响内部控 制有效性评价结论的因素。 二、内部控制评价依据 中信证券股份有限公司 关于三诺生物传感股份有限公司 202 ...

| 证券代码：300298 | 证券简称： | 三诺生物 | 公告编号：2023-032 | | --- | --- | --- | --- | | 债券代码：123090 | 债券简称： | 三诺转债 | | 三诺生物传感股份有限公司 关于第三期员工持股计划修订说明的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 三诺生物传感股份有限公司（以下简称"公司"）于 2024 年 4 月 24 日召开 第五届董事会第十次会议，审议通过《关于〈三诺生物传感股份有限公司第三期 员工持股计划（草案修订稿）〉及其摘要的议案》，同意对公司第三期员工持股计 划（以下简称"第三期员工持股计划"）及其摘要相关内容进行修订。根据公司 股东大会授权，本次修订事项在董事会审批权限范围内，无需提交公司股东大会 审议。现将主要修订内容公告如下： 一、第三期员工持股计划的基本情况 公司于 2024 年 1 月 2 日、2024 年 1 月 19 日，分别召开第五届董事第八次 会议、第五届监事会第八次会议和 2024 年第一次临时股东大会，审议并通过《关 于〈三诺生物传感股份有限公司第三 ...

| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2024-025 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 关于2023年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 三诺生物传感股份有限公司（以下简称"公司"）于 2024 年 4 月 24 日召开 第五届董事会第十次会议和第五届监事会第九次会议，审议并通过《关于〈公司 2023 年度利润分配预案〉的议案》，该议案尚需提请公司 2023 年年度股东大会 审议，现将具体情况公告如下： 经信永中和会计师事务所（特殊普通合伙）出具的标准无保留意见审计报告， 公司 2023 年度按照合并报表口径实现归属于上市公司所有者的净利润 284,397,911.89 元，母公司实现净利润为 315,280,082.61 元。根据《公司法》和 《公司章程》的有关规定，公司法定公积金累计额达到公司注册资本的 50%以上 的，可以不再提取。本次公司提取 10%的法定盈余公积金 31,528,008.26 ...

三诺生物传感股份有限公司 2023 年度内部控制自我评价报告 根据《企业内部控制基本规范》及其配套指引的规定和要求，结合三诺生物传感 股份有限公司(以下简称"公司")内部控制制度和评价办法，在内部控制日常监督和 专项监督的基础上，我们对公司截至2023年12月31日（内部控制评价报告基准日）的 内部控制有效性进行了自我评价。报告如下： 一、重要声明 按照企业内部控制规范的规定，建立健全和有效实施内部控制，评价其有效性， 并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内 部控制进行监督。经理层负责组织领导企业内部控制的日常运行。 公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存在任何虚 假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别 及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关 信息真实完整，提高经营效率和效果，促进企业实现发展战略。由于内部控制存在的 固有局限性，故仅能为实现上述目标提供合理保证。此外，由于情况的变化可能导致 内部控制变得不恰当，或对控制政策和程序遵循的程度降低，根据内部控制评价结果 ...

Global Market Presence and Sales Network - The company has established a sales and service network covering over 220,000 terminals in mainland China and 135 countries globally through its subsidiaries PTS and Trividia[3] - The company's products have completed registration in 85 countries and regions, meeting global market demands[5][7] - The company holds over 50% of China's blood glucose meter retail market, covering 3,500 hospitals, 220,000 pharmacies, and 9,000 community hospitals, with over 50% of diabetes self-monitoring patients in China using its products[43] - The company has over 25 million users globally, with operations in 135 countries and product registrations in 85 countries[43] - The company has established a global sales network covering 135 countries and regions through the collaborative sales of Sinocare, PTS, and Trividia products[168] Product Portfolio and Innovation - The company's iPOCT system can detect over 70 indicators related to diabetes and chronic diseases[17] - The company's product portfolio includes various series of home glucose monitoring systems, uric acid monitoring products, and dual-function glucose/uric acid testers[18] - The iCARE portable fully automatic multi-function tester can currently detect over 70 indicators, covering more than 2000 diseases including diabetes, inflammation, coagulation, digestion, liver function, and kidney function[20] - The company's products include the High-Sensitivity Troponin I (hs-cTnI) Detection Kit and Zinc Transporter 8 (ZnT8) Antibody Detection Kit, both classified as Class II medical devices[53] - The Glycated Hemoglobin Detection Kit is used for quantitative detection of HbA1c concentration in human whole blood, aiding in diabetes diagnosis and blood sugar monitoring[53] - The company's products also include the Triiodothyronine (T3) Detection Kit and Thyroxine (T4) Detection Kit, both for quantitative detection in serum or plasma[53] - The Anti-Thyroid Peroxidase Antibody (Anti-TPO) Detection Kit is used for quantitative detection of Anti-TPO in serum or plasma[53] - The Myoglobin (MYO) Detection Kit is used for quantitative detection of MYO in serum or plasma[53] - The D-Dimer Detection Kit is used for quantitative detection of D-Dimer in plasma[53] - The company has developed a multi-indicator chronic disease detection product system, focusing on blood glucose and expanding into diabetes-related medical services[43] - The company has established a multi-indicator detection product system based on blood glucose, with 5 product lines and over 20 sub-brands[191] Diabetes and Chronic Disease Management - The company's diabetes management model includes a personalized "AI + Six Disciplines Co-management" approach, involving a team of specialists for comprehensive patient care[3] - The company's global service network and professional medical teams provide end-to-end solutions for diabetes and chronic disease management[4] - The company's diabetes health services include chronic disease system evaluation, standardized treatment, full-course health management, education, and psychological counseling for patients with diabetes, obesity, and hyperuricemia[20] - The company has established a multi-functional chronic disease management center focusing on diabetes reversal through multi-disciplinary interventions and personalized management[20] - The company's diabetes management system integrates "biosensors + internet + medical + services" to achieve full-course management for in-hospital and out-of-hospital patients[26] - The AGEscan advanced glycation end product fluorescence detector uses non-invasive technology to assess future diabetes risk for sub-healthy, high-risk, and pre-diabetic populations[26] - The company aims to expand its market share in diabetes and related chronic disease detection, enhancing its product and service capabilities[116] - The company is focusing on digital transformation, connecting instruments with users, users with data, and data with health service providers to offer comprehensive health management services for diabetes and chronic disease patients[193] Quality Management and Certifications - The company has obtained multiple international certifications, including ISO13485, ISO 9001, CE IVDR, MDR, FDA, and MDSAP[5] - The company's production system is certified under ISO 13485:2016 and complies with Brazil BGMP, US FDA, and EU CE standards, utilizing AI, big data, and BI dashboards for quality and efficiency improvements[22] - In 2023, the company obtained the MDSAP certificate, covering Australia, Brazil, Canada, Japan, and the US, and was selected as a "Hunan Province Manufacturing Quality Benchmark"[22] - The company's procurement system follows strict supplier selection criteria, ensuring quality from the source through a qualified supplier directory[21] - The company implements a centralized procurement system for raw materials, auxiliary materials, and packaging materials, adhering to principles of appropriate price, timing, location, quality, and quantity[21] - The company has established a comprehensive quality management system, including PFMEA, TMV, and QCC, to ensure product safety and stability[25] - The company has established an international quality management system that complies with ISO 13485, ISO 9001, and other relevant regulations and standards, but faces potential quality control risks as production scales up[155] - A Quality Management System (QMS) has been implemented to integrate complaint systems across various channels, enabling unified data management and analysis for customer complaints[171] Financial Performance and Investments - Cash and cash equivalents decreased compared to the same period last year, mainly due to a reduction in net cash flow from investment activities[60] - Investment income was RMB 733,004.45, accounting for 0.29% of total profit, mainly due to cash dividends received from Note Health[61] - Asset impairment loss was RMB -116,745,988.41, accounting for -46.97% of total profit, mainly due to goodwill impairment of Trividia and inventory write-downs[61] - Other income was RMB 82,172,941.15, accounting for 33.06% of total profit, mainly due to software tax refunds and government subsidies[61] - The company provided a mortgage guarantee of RMB 155,695,534.33 for its subsidiary Changsha Xinnuo Health Industry Investment Co., Ltd., with the guarantee period ending on February 1, 2025[64] - The company raised RMB 502,649,986.28 through a private placement in 2018, with a net amount of RMB 485,911,986.55 after deducting issuance costs[66] - The company issued convertible bonds totaling RMB 500,000,000.00 in 2020, with a net amount of RMB 490,033,873.32 after deducting issuance costs[67] - The Chronic Disease Health Management Monitoring Product Capacity Expansion Project achieved 100% investment progress with a total investment of RMB 8,522.42[68] - The Smart Health Project (Internet + Biosensing + Health Management) achieved 101.02% investment progress with a total investment of RMB 25,990.39[68] - The CGMS (Continuous Glucose Monitoring System) R&D and Clinical Validation Project achieved 91.95% investment progress with a total investment of RMB 13,919.73[68] - The company invested RMB 496.73 million in cash to subscribe to an additional registered capital of RMB 33.91 million in Changsha Sinocare Health Industry Investment Co., Ltd., holding 55% of its shares[85] - The company invested RMB 496,732,672 to acquire a 55% stake in Changsha Xinnuo Health Industry Investment Co., Ltd, making it a subsidiary and consolidating it into the financial statements[98] - Changsha Funuo Medical Technology Co., Ltd received an investment of RMB 27,000,000, with the company contributing RMB 5,400,000 and EOFlow Co., Ltd contributing RMB 3,600,000[98] - Total investment in the two companies amounted to RMB 523,732,672[98] - In 2018, the company raised RMB 50,265 million through a private placement, with a net amount of RMB 48,591.2 million, and RMB 14,340.05 million (28.53%) of the funds were repurposed[101] - In 2020, the company raised RMB 50,000 million through a public offering of convertible bonds, with a net amount of RMB 49,003.39 million, and no funds were repurposed[101] - The total raised funds from both offerings amounted to RMB 100,265 million, with RMB 14,340.05 million (14.30%) repurposed and RMB 2,300.01 million still unused[101] - Prior to the 2018 fundraising, the company used RMB 1,802.06 million of its own funds to pre-invest in the projects, which was later replaced with the raised funds[102] - The company has unused raised funds of RMB 18.56 million and RMB 4.44 million, stored in specific bank accounts for future use[106] - The company has completed the construction of new production capacity for chronic disease health management monitoring products, with remaining funds redirected to the CGMS (Continuous Glucose Monitoring System) R&D and clinical validation project[106] - The CGMS (Continuous Glucose Monitoring System) capacity construction project has a planned investment of 15,000万元, with 14,848.51万元 already invested, achieving 98.99% of the planned investment[123] - The supplementary working capital project has a planned investment of 9,003.39万元, with 9,004.79万元 already invested, exceeding the planned investment by 100.02%[123] - The total planned investment for all projects is 97,594.59万元, with 97,511.97万元 already invested, achieving nearly 100% of the planned investment[123] - The CGMS (Continuous Glucose Monitoring System) clinical trials and international registration work have been delayed, with the expected completion date extended to December 2024[123] - The iPOCT (Intelligent Point-of-Care Testing) product capacity expansion project and CGMS capacity construction project have been delayed, with the expected completion date extended to January 2024[123] - The company's subsidiary, Xinno Health, generated revenue of 106,585.81万元 in the reporting period, contributing to an increase in goodwill of 71,223.81万元 and a negative impact on net profit of 17,994.85万元[130] - The company's subsidiary, Changsha Sinocare Health Industry Investment Co., Ltd., reported a net loss of 179.9 million RMB in 2023[135] - The company's subsidiary, Sinocare Health Management Co., Ltd., achieved a net profit of 49.48 million RMB in 2023[135] Strategic Initiatives and Future Plans - The company's "One Sinocare" initiative aims to integrate all subsidiaries under a unified mission, vision, and values while maintaining operational independence[15] - The company aims to enhance production quality and service efficiency while optimizing its global supply chain to improve competitiveness[2] - The company's CGM product launch marks the beginning of its second growth curve, aiming to become a global leader in diabetes digital management[34] - The company is leveraging biosensor, IoT, and AI technologies to provide smarter and more convenient diabetes management solutions[34] - The company is focused on expanding its existing business while building a user base through CGM direct connections[34] - The company plans to achieve revenue of RMB 4.6 billion in 2024, aiming for steady growth in overall sales and operating profit[115] - The company will focus on digital transformation to provide precise services for diabetic patients, aiming to standardize the diagnosis and treatment process[118] - The company aims to expand its market share in diabetes and related chronic disease detection, enhancing its product and service capabilities[116] - The company will continue to strengthen its global presence, particularly in the CGM (Continuous Glucose Monitoring) market, with plans for full-channel sales in China, Europe, and Southeast Asia, and clinical registration in the U.S.[114] - The company is committed to maintaining high-quality standards, with a focus on global compliance and continuous improvement of its quality management system[118] - The company will continue to innovate and develop new products and technologies, particularly in the field of diabetes management, to enhance its competitive edge globally[114] - The company aims to focus on the development strategy of becoming a "global leader in diabetes digital management" amidst global aging and diabetes challenges[136] - The company plans to promote the digital transformation of diabetes management experts and accelerate global collaboration to drive the formation of the second curve[137] - The company will continue to innovate in 2024, focusing on professionalization, digitalization, and globalization, and enhancing R&D efforts to provide valuable products and services[143] - The company aims to expand into global emerging markets, deepen the precision cultivation model, and promote collaboration among Sinocare, PTS, and Trividia's global marketing systems[150] - The company plans to transition from BGM to BXM, expand from POCT to PDL (Precision Desk Lab), and from CGM to PWS (Precision Wearable System) to manage chronic diseases more effectively[152] - The company will increase R&D investment to accumulate product and technology reserves, achieve product iteration and upgrade, improve production management systems, enhance efficiency, reduce costs, optimize product quality, and strengthen product and brand marketing to improve customer experience[155] - The company is actively addressing risks from industry policy changes by strengthening risk management, optimizing marketing systems, and increasing investment in emerging markets and product R&D[159] - The company is integrating overseas acquisitions Trividia and PTS, focusing on cultural, operational, and business synergies, but faces challenges in managing cultural differences and operational complexities[159] - The company is expanding its clinical market with products like the "Gold" series, dual-function products, iPOCT detection systems, and diabetes digital health management systems, gaining recognition from hospitals and primary care institutions[168] - The company is accelerating the development of primary healthcare services, expanding POCT product sales, and exploring online and offline chronic disease management services for primary healthcare institutions[168] - The company is actively expanding overseas markets, establishing subsidiaries in Vietnam, Philippines, Indonesia, India, Bangladesh, and Thailand, and leveraging PTS and Trividia to explore markets in North America, Europe, and other regions[168] - The company is expanding its multi-indicator detection system and minute diagnosis system to grassroots medical institutions, leveraging 5G technology and internet-based remote quality control to enhance service efficiency and response times[170] - The company is focusing on digital transformation to improve operational efficiency and quality, while also enhancing organizational management through cultural and global collaboration initiatives[173] - To mitigate quality control and product liability risks, the company is increasing automation in production lines, improving internal quality audit systems, and strengthening employee quality awareness[174] - The company is collaborating with Trividia and PTS in the U.S. to deepen cooperation in product R&D and large-scale production, aiming to master core technologies and adapt to market and policy changes[176] - The company is addressing the risk of overseas M&A integration by establishing collaborative mechanisms with overseas subsidiaries, focusing on operational management, product R&D, and international market expansion[179] - The company has been recognized as a "National Enterprise Technology Center" and "National Green Factory," and has received multiple national innovation fund supports, along with ISO13485 and CE certifications[184] - The company has transitioned from a blood glucose monitoring system provider to a provider and service provider of chronic disease point-of-care testing (POCT) products through global collaboration with overseas subsidiaries[185] - The company is leveraging AI and AIGC to enhance overall efficiency and address uncertainties in the competitive business environment[198] R&D and Technological Advancements - R&D investment in 2023 reached 356.41 million yuan, accounting for 8.78% of revenue, up from 7.75% in 2022 and 6.88% in 2021[35] - The company's production line automation rate exceeds 90%, significantly improving manufacturing capabilities and intelligent management levels[138] - The company is leveraging biosensor, IoT, and AI technologies to provide smarter and more convenient diabetes management solutions[34] - The company is focusing on digital transformation, connecting instruments with users, users with data, and data with health service providers to offer comprehensive health management services for diabetes and chronic disease patients[193] - The company is leveraging AI and AIGC to enhance overall efficiency and address uncertainties in the competitive business environment[198] Market Trends and Industry Analysis - The global blood glucose monitoring market grew from $17.5 billion in 2015 to $32.4 billion in 2022, with a CAGR of 9.2%, while China's market reached 12.96 billion yuan, a 14.79% YoY increase[39] - The global CGM market is dominated by Dexcom, Abbott, and Medtronic, with domestic CGM product approvals accelerating significantly since 2021[40] - The global aging population and unhealthy lifestyles are driving increased demand for lipid and glucose monitoring, with POCT technology advancements expected to boost the industry[86] Subsidiaries and Acquisitions - The company established SINOCARE MEDICAL (SINGAPORE) PTE. LTD. and acquired SINOCARE VIETNAM L&M COMPANY LIMITED to meet the demand in the Southeast Asian market and enhance international competitiveness[128] - The company's subsidiary, Xinno Health, became a wholly-owned subsidiary, aligning with the company's strategic development plan and expanding its industrial layout[128] - The company's subsidiary, Changsha Sinocare Health Industry Investment Co., Ltd., reported a net loss of 179.9 million RMB in 2023[135] - The company's subsidiary, Sinocare Health Management Co., Ltd., achieved a net profit of 49.48 million RMB in 2023[135] Operational Efficiency and Automation - The company's domestic factory has achieved large-scale automated production by leveraging the automation experience of its overseas subsidiaries PTS and Trividia[8] - The company's production line automation rate exceeds 90%, significantly improving manufacturing capabilities and intelligent management levels[138] - To mitigate quality control and product liability risks, the company is increasing automation in production lines, improving internal quality audit systems, and strengthening employee quality awareness[174] Financial and Investment Risks - The company is actively addressing risks from industry policy changes by strengthening risk management, optimizing marketing systems, and increasing investment in emerging markets and product R&D[159] - The company is integrating overseas acquisitions Trividia and PTS, focusing on cultural, operational, and business synergies, but faces challenges in managing cultural differences and operational complexities[159] - The company is addressing the risk of overseas M&A integration by establishing collaborative mechanisms with overseas subsidiaries, focusing on operational management, product R&D, and international market expansion[179] Sales and Distribution Strategy - The company's sales strategy combines direct sales and distribution, primarily targeting the retail market through partnerships with pharmaceutical companies, pharmacies, and e-commerce platforms[139] - The company is accelerating the development of primary healthcare services, expanding POCT product sales, and exploring online and offline chronic disease management services for primary healthcare institutions[168] Regulatory and Compliance - The company has obtained multiple international certifications,

中信证券股份有限公司 根据《三诺生物传感股份有限公司创业板向不特定对象发行可转换公司债券募集 说明书》、《关于募集资金投资项目延期的公告》（公告编号：2023-019），本次向不特 定对象发行可转换公司债券募集资金扣除相关中介费用后，将用于募集资金投资项目 的具体情况如下： 单位：人民币/万元 | 序 | 项目 | 实施主体 | 项目投资总额 | 募集资金承 | 项目达到预定可 | | --- | --- | --- | --- | --- | --- | | 号 | | | | 诺投资总额 | 使用状态日期 | | 1 | iPOCT（智慧化即时检测） 产品产能扩建项目 | 三诺生物 | 25,000.00 | 25,000.00 | 2024年1月 | | 2 | CGMS（连续血糖监测系 | 三诺生物 | 16,419.00 | 15,000.00 | 2024年1月 | 1 | 序 | 项目 | 实施主体 | 项目投资总额 | 募集资金承 | 项目达到预定可 | | --- | --- | --- | --- | --- | --- | | 号 | | | | 诺投资总额 | 使用状态日期 | | | ...